Name: ARCTURUS THERAPEUTICS HOLDIN (ARCT) Stock
Brand: ARCTURUS THERAPEUTICS HOLDIN
Rating: 4 (3 reviews)

ARCT Latest News, Press Relases and Analysis

All

Press Releases

2 days ago - By: Zacks Investment Research - Mentions: CRMD ADMA ARQT

ARCT Stock Plunges 59% in Three Months: Here's What You Need to Know

8 days ago - By: Arcturus Therapeutics Holdings Inc.

Arcturus Therapeutics to Attend Upcoming Investor Conference

22 days ago - By: Zacks Investment Research - Mentions: TCRX

Arcturus Therapeutics (ARCT) Reports Q3 Loss, Beats Revenue Estimates

22 days ago - By: Arcturus Therapeutics Holdings Inc.

Arcturus Therapeutics Announces Third Quarter 2025 Financial Update and Pipeline Progress

26 days ago - By: Benzinga

Preview: Arcturus Therapeutics's Earnings

a month ago - By: Benzinga

Where Arcturus Therapeutics Stands With Analysts

23 days ago - By: Edelson Lechtzin LLP

INVESTIGATION ALERT: Edelson Lechtzin LLP Announces Investigation of Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) and Encourages Investors with Substantial Losses to Contact the Firm

a month ago - By: Arcturus Therapeutics Holdings Inc.

Arcturus Therapeutics to Attend Upcoming Investor Conferences

a month ago - By: Zacks Investment Research - Mentions: FATE

Fate Therapeutics (FATE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

a month ago - By: Zacks Investment Research - Mentions: IOVA

Earnings Preview: Arcturus Therapeutics (ARCT) Q3 Earnings Expected to Decline

3 months ago - By: Zacks Investment Research

Should You Buy Arcturus Therapeutics (ARCT) After Golden Cross?

a month ago - By: Arcturus Therapeutics Holdings Inc.

Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 10, 2025

a month ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arcturus Therapeutics Holdings Inc. - ARCT

a month ago - By: The Motley Fool - Mentions: HOOD NFLX

Cathie Wood Goes Shopping: 3 Stocks She Just Bought

a month ago - By: Stocktwits - Mentions: VFMO IWMW

Arcturus Therapeutics Stock Plunges Over 57% Today: What’s Causing The Sell-Off?

a month ago - By: Investor's Business Daily

Arcturus Crashes 55% On 'Underwhelming' Results For mRNA-Tied Cystic Fibrosis Drug

a month ago - By: Arcturus Therapeutics Holdings Inc.

ARCTURUS THERAPEUTICS HOLDIN (ARCT) Stock News

ARCT Latest News, Press Relases and Analysis

ARCT Stock Plunges 59% in Three Months: Here's What You Need to Know

Arcturus Therapeutics to Attend Upcoming Investor Conference

Arcturus Therapeutics (ARCT) Reports Q3 Loss, Beats Revenue Estimates

Arcturus Therapeutics Announces Third Quarter 2025 Financial Update and Pipeline Progress

Preview: Arcturus Therapeutics's Earnings

Where Arcturus Therapeutics Stands With Analysts

INVESTIGATION ALERT: Edelson Lechtzin LLP Announces Investigation of Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) and Encourages Investors with Substantial Losses to Contact the Firm

Arcturus Therapeutics to Attend Upcoming Investor Conferences

Fate Therapeutics (FATE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Earnings Preview: Arcturus Therapeutics (ARCT) Q3 Earnings Expected to Decline

Should You Buy Arcturus Therapeutics (ARCT) After Golden Cross?

Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 10, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arcturus Therapeutics Holdings Inc. - ARCT

Cathie Wood Goes Shopping: 3 Stocks She Just Bought

Arcturus Therapeutics Stock Plunges Over 57% Today: What’s Causing The Sell-Off?

Arcturus Crashes 55% On 'Underwhelming' Results For mRNA-Tied Cystic Fibrosis Drug

Arcturus Therapeutics Provides Interim Phase 2 Data for Cystic Fibrosis (CF) Program